PO:20:003 | Romosozumab effect on neutrophil-to-lymphocyte ratio in post-menopausal women at high risk of fracture
Background. Romosozumab (ROMO) is a monoclonal antibody targeting sclerostin (SOST), a key regulator of bone metabolism. It has been demonstrated that changes in SOST levels can affect distinct niches within the bone marrow that support hematopoiesis. To date, no clinical studies have explored the...
Na minha lista:
| Hovedforfatter: | |
|---|---|
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
PAGEPress Publications
2025-11-01
|
| Serier: | Reumatismo |
| Fag: | |
| Online adgang: | https://www.reumatismo.org/reuma/article/view/2051 |
| Tags: |
Ingen Tags, Vær først til at tagge denne postø!
|